Bayer HealthCare's rivaroxaban shows efficacy in stroke prevention
26 May 2011 00:00 in Pharmaceutical Company Product News
Bayer HealthCare has published new data on its atrial fibrillation (AF) drug rivaroxaban that shows its effectiveness in preventing strokes.
A pre-planned subgroup analysis has been conducted for the Rocket AF phase III clinical trial to assess the performance of the developmental drug among AF patients who have experienced a prior stroke or transient ischemic attack.
It was found to outperform warfarin, the current standard of care, in reducing the risk of stroke and systemic embolism among this group.
This could be a potentially significant discovery, as clinicians are currently reliant on warfarin to prevent AF-related stroke, despite the well-known side effects associated with the drug.
Professor Werner Hacke, chair of the department of neurology at the University of Heidelberg, said: "The Rocket AF study has given us a unique opportunity to compare existing care with a new-generation medicine that does not have the same limitations as warfarin."
At the American Society of Clinical Oncology (ASCO) annual meeting on the 3rd of June, the company will present data on compounds, including Alpharadin.
Other news stories from 26/05/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency